Strategic Merger Stelis Biopharma recently merged with SteriScience and Strides to form OneSource Specialty, signaling a large-scale platform for biologics CDMO capabilities and potential cross-sell opportunities across a broader customer base seeking integrated development and manufacturing solutions.

Integrated CDMO Scale As a fully integrated biopharma CDMO with capabilities from cell line development to fill/finish, Stelis can target clients needing end-to-end biologics development and manufacturing, offering a single partner to reduce timelines and complexity.

Bengaluru footprint Strategic presence in Bengaluru with Unit 2 flagship facilities and ongoing expansion indicates capacity to serve global biologics programs from a cost-competitive, innovation-driven hub, appealing to customers seeking scalable manufacturing in India.

GLP-1 & Biologics Focus The merger context and emphasis on biologics manufacturing positions Stelis to pursue partnerships in high-growth therapeutic areas like GLP-1 and other protein-based drugs, presenting opportunities with pharma companies expanding biologics portfolios.

Growth via Partnerships Past and ongoing partnerships and divestitures with Syngene and Synoptics, combined with the OneSource platform, create openings for co-development, capacity sharing, and strategic alliances with mid-to-large biopharma firms seeking reliable CDMO collaboration for scale-up and commercial readiness.